Lir Life SciencesBBCMF -80.00%15 Current Ratio is 13.26 as of Jan. 2026, which is 1407% above its 10-year median of 0.88. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,417 Biotechnology companies, Lir Life Sciences ranks better than 83.98% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lir Life Sciences's current ratio for the quarter that ended in Jan. 2026 was 13.26.
Lir Life Sciences has a current ratio of 13.26. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Lir Life Sciences's Current Ratio or its related term are showing as below:
BBCMF'
s Current Ratio Range Over the Past 10 Years
Min: 0.04 Med: 0.88 Max: 28.15
Current: 13.35
During the past 2 years, Lir Life Sciences's highest Current Ratio was 28.15. The lowest was 0.04. And the median was 0.88.
BBCMF's Current Ratio is ranked better than 83.98% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs BBCMF: 13.35
Lir Life Sciences (OTCPK:BBCMF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lir Life Sciences Current Ratio Related Terms
Lir Life Sciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBCMF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Lir Life Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lir Life Sciences (BBCMF) has a Current Ratio of 13.26 as of Jan. 2026. This is 1407% above median its historical median of 0.88. Over the past decade, Lir Life Sciences' Current Ratio has ranged from 0.04 to 28.15. According to the industry distribution chart, Lir Life Sciences ranks #227 out of 1417 companies in the Biotechnology industry, placing it in the top 16%.
Is Lir Life Sciences' Current Ratio too high?
Lir Life Sciences' current Current Ratio of 13.26 is 1407% above median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 28.15. The Biotechnology industry median Current Ratio is 3.89. Lir Life Sciences' value of 13.26 is 240.9% above this industry median. Based on the distribution chart, Lir Life Sciences ranks #227 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #227 out of 1417 companies for Current Ratio. This places Lir Life Sciences in the top 16% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Lir Life Sciences' value of 13.26 is 240.9% above this benchmark. Historically, Lir Life Sciences' own Current Ratio has ranged from 0.04 to 28.15 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 3.89, Lir Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lir Life Sciences's current Current Ratio of 13.26 is 240.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current Current Ratio is 13.26, which is 1407% above median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Current Ratio of 13.26. The current Current Ratio is 13.26, which is 1407% above median its 10-year median of 0.88 and 240.9% above the Biotechnology industry median of 3.89. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Current Ratio is 13.26 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score
Get the complete analysis for BBCMF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 